Aguiar-Oliveira · Endocrine reviews 2019 · narrative review · n=?

Growth Hormone Deficiency: Health and Longevity.

Cited 201 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing findings from rodent genetic models and observational human cohort studies.

PubMed 30576428 · doi:10.1210/er.2018-00216 · record verified 2026-08-26

What was done

The authors reviewed evidence linking growth hormone (GH) deficiency and GH resistance to longevity and healthspan across mammalian species. They synthesized findings from genetic mouse models (including isolated GH deficiency, combined pituitary hormone deficiencies, and global GH receptor knockouts) and observational data from a human cohort in Itabaianinha County, Brazil, who possess isolated GH deficiency (IGHD) type 1B resulting from a GHRH receptor gene mutation.

What was found

The abstract reports qualitative findings across species. Mice with reduced GH signaling exhibited extended lifespan, delayed or slower aging characteristics, and extended healthspan. In the Brazilian IGHD cohort, affected individuals presented with proportional short stature, doll facies, high-pitched voices, central obesity, and delayed puberty, while remaining fertile and generally healthy. These individuals showed partial protection against cancer and common age-related effects, with documented extreme longevity (reaching up to 103 years of age in one reported case). The authors propose that low residual GH secretion paired with lifelong low circulating IGF-1, while preserving local tissue IGF-1/2 levels, explains these healthspan and longevity outcomes.

Why it matters

This review highlights an evolutionarily conserved trade-off between somatic growth/anabolic signaling and longevity. It suggests that severe down-regulation of the GH/IGF-1 axis may confer protection against age-related morbidity and cancer in humans without compromising overall lifespan.

Limits

The human evidence relies primarily on a single, genetically distinct, geographically isolated cohort with an uncommon GHRH receptor mutation, limiting generalizability to broader populations. The abstract provides no quantitative sample sizes, hazard ratios, or comparative incidence rates, preventing independent evaluation of effect magnitudes.

Cited by